Financing ·
NewcelX Ltd. announced the pricing of a $1.4 million private equity financing on July 31, 2026
NLSPWNLS Pharmaceutics Ltd.
NewcelX Ltd. announced the pricing of a $1.4 million private equity financing on July 31, 2026. The company sold 347,134 common shares at $4.033 per share, representing a 20% premium to the previous closing price, alongside warrants for an equal number of shares at $4.437. Proceeds will advance NCEL-101, its lead type 1 diabetes program, and support working capital. The transaction is expected to close around August 14, 2026. NewcelX Ltd. operates in the biopharmaceutical industry, developing stem cell-based therapies for type 1 diabetes.